Imugene share price (ASX:IMU) pops 5% in cancer trial update

Why is this cancer therapy company impressing investors today?

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Imugene Limited (ASX: IMU) share price is up today on the back of a positive cancer treatment update.

Shares in the biopharma company are currently trading at 50 cents, up 5.26%.

Let's take a look at what's going on at Imugene.

What did the company announce?

The Imugene share price is climbing today after the company announced an update regarding a phase 1 clinical trial.

Imugene is developing therapies that aim to use the body's immune system to treat cancer tumours.

Today, the company announced a second patient with triple-negative breast cancer (TNBC) has been given a dose of CHECKvacc.

CHECKvacc is an oncolytic virotherapy candidate currently in phase 1 clinical trial at the City of Hope cancer research centre in Los Angeles, USA. TNBC is an aggressive form of the disease with a survival rate of just 12 months.

The trial aims to evaluate the safety and efficacy of the administration of CHECKvacc in patients with metastatic TNBC.

The company says the current trial design will involve a dose escalation. It is also planning to expand the trial to 12 patients. The first patient treated with the cancer therapy has had no safety issues to date.

Comment from management

Speaking on the update that's likely fuelling the Imugene share price today, managing director and CEO Leslie Chong said:

We hope that in time, CHECKvacc provides an improved outcome for the many women who are diagnosed every year with triple-negative breast cancer.

We look forward to seeing the results of this trial and bringing continued updates to the medical community and our stakeholders moving forward.

Imugene share price snap shot

In the past 12 months, the Imugene share price has soared by 298%. It has also risen 398% this year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned 9% in the past year.

The share price low this year is 9 cents, while the yearly high is 63 cents.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »